Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case–control study

Authors

  • F. De Vries,

    1. From the Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands
    Search for more papers by this author
  • S. Pouwels,

    1. From the Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands
    Search for more papers by this author
  • J. W. J. Lammers,

    1. Department of Pulmonary Diseases, Utrecht Medical Center, Utrecht University, the Netherlands
    Search for more papers by this author
  • H. G. M. Leufkens,

    1. From the Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands
    Search for more papers by this author
  • M. Bracke,

    1. From the Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands
    2. Department of Pulmonary Diseases, Utrecht Medical Center, Utrecht University, the Netherlands
    Search for more papers by this author
  • C. Cooper,

    1. MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, Southampton, UK
    Search for more papers by this author
  • T. P. Van Staa

    1. From the Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands
    2. MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, Southampton, UK
    3. General Practice Research Database, London, UK
    Search for more papers by this author

Tjeerd-Pieter van Staa, Sorbonnelaan 16, 3584 CA Utrecht, the Netherlands.
(fax: +31(0)30-2539166; e-mail: t.p.vanstaa@pharm.uu.nl).

Abstract.

Background.  Patients using higher dosages of inhaled or oral glucocorticoids (GCs) have an increased risk of hip/femur fractures. The role of the underlying disease in the aetiology of this increased risk has not been widely studied.

Objective.  To evaluate the contribution of the underlying disease to the risk of hip/femur fracture in patients using inhaled or oral GCs.

Design and subjects.  A case–control study within the Dutch PHARMO-RLS database was conducted. Cases (n = 6763) were adult patients with a first hip/femur fracture during enrolment. Each case was matched to four controls by age, gender and region.

Results.  The risk of hip/femur fracture increased with current use of inhaled GCs (crude OR 1.30, 95% CI:1.16–1.47) and with current use of oral GCs (crude OR 1.66, 95% CI: 1.46–1.90). After adjustment for disease severity, the risk of hip/femur fracture was no longer statistically significantly increased in inhaled GC users (adjusted OR 1.08, 95% CI: 0.91–1.27), whilst it remained elevated in oral GC users (adjusted OR 1.43, 95% CI: 1.22–1.67). Patients using inhaled GCs without any exposure to oral GCs had no increased risk of fracture (adjusted OR 0.98, 95% CI: 0.79–1.22).

Conclusion.  Inhaled GC users had no increased risk of femur/hip fracture after adjustment for underlying disease severity. Our data suggest that, even at higher dosages, inhaled GC use is not an independent risk factor for fracture. In contrast, oral GC use was associated with an increased risk of fracture, which was not fully explained by the underlying disease severity.

Ancillary